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1. Introduction
Endophthalmitis is one of the most devastating diagnoses in ophthalmology. It is a serious
intraocular inflammatory disorder affecting the vitreous cavity that can result from exogenous
or endogenous spread of infecting organisms into the eye. [1] Endogenous endophthalmitis is
less common and occurs secondary to hematogenous dissemination from a distant infective
source in the body. Predisposing risk factors in patients with endogenous endophthalmitis
usually exist, and they are correlated with the pathogenesis of the disease.[1] The risk factors
are considered as infectious foci in the other parts of the body, intravenous drug abuse, diabetes
mellitus, immunosuppressive therapy, intravenous hyperalimentation, fever of unknown
origin, malignancies and male sex. [2-6] In most cases, independent of its origin, the presen‐
tation of endophthalmitis consists of reduced or blurred vision, red eye, pain, and lid swelling.
[7] Progressive vitritis (Fig.1) is one of the key findings in any form of endophthalmitis, and
in nearly 75% of patients have hypopyon (Fig. 2) which can be seen at the time of presentation.
[7] Progression of the disease may lead to panophthalmitis, (Fig. 3) corneal infiltration, (Fig.
4) globe perforation and phthisis bulbi.(Fig. 5) [1,7] Endogenous endophthalmitis is a rare
complication of infective endocarditis, and has been decreasing due to the availability of
effective antibiotics. [8] To optimize visual outcome, early diagnosis and treatment are
essential.[7,8] Over recent decades, advances in hygienic standards, improved microbiologic
and surgical techniques, development of powerful antimicrobial drugs, and the introduction
of intravitreal antibiotic therapy have led to a decreased incidence and improved management
of endophthalmitis. [1,7] However, endophthalmitis still represents a serious clinical problem.
This chapter focuses mainly on current principles and techniques for treatment of endoph‐
thalmitis. In addition, it addresses recent developments regarding anti-inflammatory and
antimicrobial treatments.
© 2013 Sahin; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
           
               
   
   
   
                                 
                                     
                               
                                     
                                         
                         
    ‐                                    
                                           
                                               
                             
                                   
                                 
                           
                               
                                 
                        ‐    
   
 
                               
Figure 1. Note the dense vitritis, vitreous bands, ( ) precipitates, ( ) and retinitis foci ( ) located superiorly.
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Figure 2. Note the 2-mm hypopyon ( ) in the anterior chamber associated with diffuse ciliary injection ( )
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Figure 3. Note severe panophthalmitis with superonasal scleral abscess, and extrusion of pus from the limbus. (A
Shwe-Tin, T Ung, C Madhavan and T Yasen: A case of endogenous Clostridium perfringens endophthalmitis in an in‐
travenous drug abuser. Eye (2007) 21, 1427–1428; doi:10.1038/sj.eye.6702934; published online 3 August 2007)
 
                       
 
                         
   
                                   
                                     
                                 
                                         
                             
                                 
                                       
                                     
                                       
 
Figure 4. Note the central corneal infiltration ( ) and diffuse stromal edema ( )
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Figure 5. Note the phytisis bulbi associated with diffuse corneal vascularization and opacification ( )
2. Pathogenesis
In general, inflammation is a physiological response to invading pathogens or antigens which
involve the migration of specific types of inflammatory cells out of the bloodstream into
theaffected tissues. [9,10] These cells release inflammatory agents such as cytokines, chemo‐
kines and other inflammatory markers to boost immune responses to kill the invading bacteria,
viruses, and parasites or any other antigen. [9,10] The linking of the antibody to the antigens
forms an immune complex which is removed quickly by phagocytic macrophages; however
owing to excessive antigen exposure or compromised immune response, the pathogens or their
toxins are lodged into tissues and cause severe inflammation. [11,12] Excessive inflammatory
response can damage the healthy tissues during this process. In excessive inflammation, the
affected parts of the eye (the eyelids, sclera, iris, uvea, retina, optic nerve etc) become tender
and inflamed. [11,12] Chronic or sever ocular inflammation can damage the delicate tissues
and blood vessels in and around the eye resulting in vision loss. [13] Ocular inflammatory
diseases occurs throughout the world independent of gender, race, ethnicity, or age and can
be caused due to various factors such as infection, auto-immunity, trauma, drugs, or malig‐
nancy. [13] As the infectious pathogens enter the eye via hematogenous spread bacterial
endotoxins, cytokins and growth factors induce the cellular mechanisms of reactive oxygen
species (ROS) formation. [14] The key mediators are hydrogen peroxide (H2O2), superoxide
anions and peroxinitrite (NOO−), collectively termed as ROS. [14-16] ROS are believed to
underlie many of the oxidative changes in various pathological conditions, and are known to
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enhance various mediators including increased expression of aldose reductase (AR), activation
of protein kinase C and redox-sensitive nuclear transcription factors such as NF-κB and
activator protein-1 (AP-1). [15-17] ROS in turn lead to the cell membrane lipid peroxidation
and formation of lipid aldehydes, e.g. 4-hydroxynonenal-(HNE) which conjugates with
glutathione. (GS-HNE) Aldose reductase then catalyzes reduction of GS-HNE into glutathione
1,4 dihydroxynonene (GS-DHN) which acts as a transducer of inflammatory signaling by
activating protein kinases system.[18,19] Eventually, the redox-sensitive transcription factors
including NF-κB and AP-1 are activated in the nucleus, and transcribe many inflammatory
genes that contribute to intraocular inflammation such as endophthalmitis. [19-21] Many
inflammatory mediators, such as TNF-α, IL-1β, IL-6, and inducible-nitric oxide synthase
(iNOS) require NF-κB activation for their expression as their genes possess NF-κB binding
sequences in promoter regions. [19-21] Since the discovery of NF-κB, a number of paradigms
for its function have been established including its key role in the inflammatory and immune
responses. NF-κB stimulates immune cell function and acts in a pro-inflammatory manner by
inducing the expression of cytokines, chemokines and their receptors. [19-21]These aspects of
NF-κB function are undoubtedly central to the understanding of the overall action of this
family of transcription factors, and they provide a foundation for therapeutic intervention in
inflammatory diseases based on NF-κB inhibition. [22,23] AR mediates the activation of NF-
κB during oxidative stress caused by various stimuli and that inhibition of AR attenuates the
activation of key signaling kinases leading to deactivation of NF-κB. It is plausible that AR
inhibitors could be potential therapeutic agents to treat the oxidative stress-induced ocular
inflammation. [22,23] Alternatively, it has been shown that inhibition of AR prevents NF-κB
activation in both cellular as well as animal models of ocular inflammation, thereby regulating
the synthesis and secretion of pro-inflammatory markers suggesting that inhibition of AR by
gene silencing or pharmacological agents could be an important strategy to treat ocular
inflammatory diseases. [24,25] The evidence showing that lipid peroxidation products are
being the excellent substrates of AR has led to this enzyme linked to inflammation and auto-
immune mediated oxidative stress, besides diabetic complications. [26,27] Many studies with
cell-culture and animal models of ocular inflammation have shown that inhibition of AR could
ameliorate the inflammation induced by various stimuli including bacterial endotoxin,
lipopolysachharide (LPS), high glucose, and cytokines. [24-27]The increased expression of AR
in human cornea, lens, retina, and optic nerve has been shown during oxidative stress. [28,29]
More recent reports suggest an unanticipated link between AR and ocular inflammation, e.g.
inhibition of AR by pharmacological agents or by mRNA ablation leads to the prevention of
high glucose-, TNF-α-, and LPS-induced oxidative stress in human lens epithelial cells (HLEC)
suggesting that AR could be another molecular target for the treatment of oxidative stress-
induced ocular inflammation. [27] Although the eye is an immunologically privileged organ,
it can also get damaged from the excessive immune response of the body when blood ocular
barrier function is compromised. [30] Both in-vitro and in-vivo studies have demonstrated that
AR inhibition or ablation prevents the activation of PKC/NF-κB thereby attenuate cytotoxicity
and tissue damage. [31] It has also been shown that AR inhibition in rodent endotoxin-induced
uveitis model leads to attenuation of ocular inflammation as characterized by decreased
protein extravasations and cellular infiltration into the anterior chamber [24]. These results
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demonstrated that AR inhibition leads to in-vivo suppression of NF-κB that can attenuate
inflammation in the eye. In HLEC, it has recently been shown that AR mediates the LPS-
induced cytotoxicity via the activation of redox sensitive transcription factors NF-κB and AP-1,
and inhibition of AR by pharmacological inhibitor or by silencing the AR expression by AR
siRNA prevented the cytotoxicity caused by LPS. [32] These findings are significant as LPS –
induced ocular inflammation, such as endogenous endophthalmitis in which infection reaches
the eye via circulation and infection-induced uveitis, are well known threats to vision in
humans. [33,34] Inhibition of such inflammation by AR inhibitors provides a novel therapeutic
approach for infection –induced ocular diseases. Further, a study by Kubo et al showed that
over-expression AR in HLEC led to the increased oxidative stress and apoptosis, and inhibition
of AR prevented the cells from oxidative stres. [35] In a recent study, it has been demonstrated
that AR mediates LPS-induced cytotoxicity in non-pigmented ciliary epithelial cells and
disturbs the aqueous humor dynamics by altering the expression of channel proteins such as
Na-K-ATPase. [36] This study has greater implication in the infection-induced ocular inflam‐
mation as reduced flow of aqueous humor could result in severe vision impairment or vision
loss. Besides, attraction of macrophages to the ocular tissues or activation of resident macro‐
phages e.g. dendritic cells during inflammation cause severe damage to the ciliary body and
retinal layers. [33-35] The role of AR in LPS-induced inflammation and macrophage activation
is important because macrophages play an important role in the ocular inflammation such as
uveitis. Macrophages infiltrate the vasculature and enter the aqueous humor in anterior
segment releasing enormous amount of cytokines and chemokines that result in the patho‐
logical symptoms of uveitis such as flare, cell, edema, and vasodilation. [37] Therefore, it is
significant in the way that AR inhibition provides a novel therapeutic target in ocular inflam‐
matory diseases. Studies in the cellular models provide an evidence of an unanticipated role
of AR in mediating acute inflammatory responses, and also inhibition of AR might be thera‐
peutically useful in preventing ocular inflammation induced by oxidative stress especially in
various pathological conditions.
3. Basic principles in the treatment of endogenous
3.1. Endophthalmitis
The therapy of infectious endophthalmitis remains a controversial issue because progression
and suboptimal outcome occur despite bacteriologic cure of the intraocular infection. The
irreversible tissue destruction during the inflammatory process may result largely from a
secondary host inflammatory response. However, adjunctive treatment with immunosup‐
pressive agents may interfere with the ability of the immune system to eliminate the micro‐
organisms. Hence the option of adjunctive immunosuppression in the therapy of infectious
endophthalmitis is still on debate. Endogenous endophthalmitis is treated by a combination
of broad-spectrum antibiotics (vancomycin and ceftazidime or amikacin), which are admin‐
istered intravitreally, subconjunctivally and topically, if appropriate in combination by
systemic antibiotics (vancomycin and ceftazidime or amikacin). [1,2] If vision diminishes to
mere light perception, performance of pars plana vitrectomy is indicated. [2-4] In mycotic
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endophthalmitis, antimycotics (amphotericin B) are administered intravitreally. [38,39] If
findings are severe, a pars plana vitrectomy must also be carried out. [40,41] Antimycotics are
applied topically to support treatment. [38] Systemic therapy with antibiotics or mycotics is
obligatory. [42]
3.2. Topical antimicrobial agents
Fluoroquinolones are especially useful because they possess a broad antibacterial spectrum,
bactericidal in action, are generally well tolerated, and have been less prone to development
of bacterial resistance. [43]
Second-generation fluoroquinolones; Ciprofloxacin 0.3% and Ofloxacin 0.3% have been
widely used in the treatment and prophylaxis of ocular infections. [43,44] However, their in-
vitro potencies have been decreasing steadily since their introduction. But ciprofloxacin
remains the most effective fluoroquinolone against gram-negative bacteria. Minimal inhibi‐
tory concentration at 90% level (MIC90) for ciprofloxacin is lower in gram-negative bacteria.
MIC90 for ofloxacin is higher against Haemophilus spp. and Moraxella spp. Ciprofloxacin is
clinically the most potent fluoroquinolone for Pseudomonas spp. Ciprofloxacin is just as potent
as gatifloxacin for the other gram-negative isolates.[44]Third-generation fluoroquinolones;
Levofloxacin 0.5% produces higher ocular tissue penetration, thereby reducing the risk of
selecting for decreased fluoroquinolone potency. A new third-generation formulation,
levofloxacin 1.5%, is recently introduced, demonstrating increased ocular penetration com‐
pared with gatifloxacin 0.3%, but clinical equivalence to its second-generation parent, ofloxacin
0.3%, in two randomized trials. [45]Fourth-generation fluoroquinolones; Fourth-generation
agents have increased potency against gram-positive bacteria compared with levofloxacin,
while maintaining similar potency against gram-negative bacteria. [46] Although levofloxacin
1.5% has demonstrated superior ocular penetration relative to gatifloxacin, the limited
available data do not suggest this translates into superior clinical activity compared with
moxifloxacin, which has significantly greater ocular penetration and better gram-positive
potency than gatifloxacin. [46] Gatifloxacin 0.3% and moxifloxacin 0.5% have structural
modifications that both reduce risk of resistance and improve potency against gram-positive
bacteria. Fourth-generation agents have increased potency against gram-positive bacteria
compared with levofloxacin, while maintaining similar potency against gram-negative
bacteria. [47] From susceptibility profiles achieved with in vitro testing, the fourth-generation
fluoroquinolones may offer some advantages over the currently available fluoroquinolones;
however, a combination of the pharmacodynamics and pharmacokinetics of the drug, infection
site, and the MIC90 is needed to predict the in vivo efficacy and best clinical applicability. [47]
The fourth-generation fluoroquinolones are clinically more potent than the second generations
for gram-positive bacteria. The MIC90 level is lower for moxifloxacin than that for gatifloxacin
against Staphylococcus aureus, methicillin-susceptible coagulase-negative Staphylococcus
(CoNS), and Streptococcus pneumoniae, whereas the levels are equal against Streptococcus
viridans and the gatifloxacin MIC90 is lower in methicillin-resistant coagulase-negative CoNS
[48] With in vitro tests, Staphylococcus aureus isolates that are resistant to ciprofloxacin and
ofloxacin are clinicallymost susceptible to moxifloxacin. CoNS, that are resistant to ciproflox‐
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acin and ofloxacin are clinically most susceptible to moxifloxacin and gatifloxacin.
[48]Streptococcus viridans are more susceptible to moxifloxacin, gatifloxacin and levofloxacin
than ciprofloxacin and ofloxacin. Streptococcus pneumoniae is least susceptible to ofloxacin
compared with the other fluoroquinolones. [48] Susceptibilities are found equivalent for all
other bacterial groups. In general, moxifloxacin is the most potent fluoroquinolone for gram-
positive bacteria, while ciprofloxacin, moxifloxacin, gatifloxacin, and levofloxacin demon‐
strate equivalent potencies to gram-negative bacteria. [45,47] None of the fluoroquinolones are
effective against ciprofloxacin-resistant gram-negative bacteria. Overall, for gram-positive
bacteria, median MIC90s of levofloxacin, moxifloxacin and gatifloxacin are below ciprofloxa‐
cin, the MIC90 of gatifloxacin and moxifloxacin is equal for gram-positive bacteria. Levoflox‐
acin, gatifloxacin and moxifloxacin are clinically more effective against gram-positive bacteria,
the latter two being equally effective. Ciprofloxacin remains the most effective fluoroquinolone
against gram-negative bacteria. [45,48] Fourth-generation fluoroquinolone moxifloxacin,
seems to have better penetration to the inflamed ocular tissues in rabbit. [49] Moxifloxacin has
a spectrum of coverage that encompasses the most common organisms in endophthalmitis.
[49] Because of their broad spectrum of coverage, low MIC90, good tolerability, and excellent
oral bioavailability, fourth-generation fluoroquinolones are considered to represent a major
advance for managing posterior segment infections. [47,49]
Delivery of moxifloxacin via a collagen shield is recommended when high concentrations of
moxifloxacin are most needed to clear the aqueous of bacteria. [50] There are several advan‐
tages of this route of delivery that make it appealing over the frequent topical drop use in the
immediate period. [50] Future studies are considered to define precisely the role of fourth-
generation fluoroquinolones and presoaked collagen shields in the prophylaxis or manage‐
ment of intraocular infections.
Orally administered gatifloxacin achieves therapeutic levels in the noninflamed human eye,
and the activity spectrum appropriately encompass the bacterial species most frequently
involved in the various causes of endophthalmitis. Because of its broad-spectrum coverage,
low MIC90 levels for the organisms of concern, and good tolerability, gatifloxacin represents
a major advance in the prophylaxis or treatment of bacterial endophthalmitis including
Staphylococcus epidermidis, Staphylococcus aureus, Streptococcus pneumoniae, Streptococ‐
cus pyogenes, Propionibacterium acnes, Haemophilus influenzae, Escherichia coli, Bacillus
cereus, Proteus mirabilis, and other organisms. [51] Besifloxacin, the latest advanced fluoro‐
quinolone approved for treating bacterial conjunctivitis is the first fluoroquinolone developed
specifically for topical ophthalmic use. [52] It has a C-8 chlorine substituent and is known as
a chloro-fluoroquinolone. Besifloxacin possesses relatively balanced dual-targeting activity
against bacterial topoisomerase IV and DNA gyrase (topoisomerse II), two essential enzymes
involved in bacterial DNA replication, leading to increased potency and decreased likelihood
of bacterial resistance developing to besifloxacin. [52] Microbiological data suggest a relatively
high potency and rapid bactericidal activity for besifloxacin against common ocular pathogens,
including bacteria resistant to other fluoroquinolones, especially resistant staphylococcal
species. [52,53] Randomized, double-masked, controlled clinical studies demonstrated the
clinical efficacy of besifloxacin ophthalmic suspension 0.6% administered three-times daily for
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5 days to be superior to the vehicle alone and similar to moxifloxacin ophthalmic solution 0.5%
for bacterial conjunctivitis. [53] In addition, besifloxacin ophthalmic suspension 0.6% admin‐
istered two-times daily for 3 days isclinically more effective than the vehicle alone for bacterial
conjunctivitis. Besifloxacin has also been shown in preclinical animal studies to be potentially
effective for the "off-label" treatment of infections following ocular surgery, prophylaxis of
endophthalmitis, and the treatment of bacterial keratitis. Taken together, clinical and preclin‐
ical animal studies indicate that besifloxacin is an important new option for the treatment of
ocular infections. [53]Both besifloxacin and moxifloxacin achieved aqueous humor concentra‐
tions equal to or slightly higher than their respective MIC90 for methicillin-resistant and
methicillin-susceptible Staphylococcus aureus and Staphylococcus epidermidis; none of the
fluoroquinolones achieved concentrations above their MIC90 for ciprofloxacin-resistant
strains of Staphylococccus aureus and Staphylococcus epidermidis. [54] Based on the aqueous
humor drug concentrations measured, it is unlikely that any of the fluoroquinolones tested
would be therapeutically effective in the aqueous humor against the most frequently identified
drug-resistant Staphylococcal isolates from cases of endophthalmitis. [54] As well as; none of
the fluoroquinolones reduce the number of bacteria recovered from the vitreous humor. [54]
Besifloxacin is as effective as moxifloxacin and gatifloxacin in a rabbit model for topical
prophylaxis and treatment of pneumococcal endophthalmitis. [55] Besifloxacin acts as an anti-
inflammatory agent in corneal epithelial cells in vitro, by inhibiting the nuclear factor, NF-κB
and mitogen-activated protein kinase (MAPK) pathways. Besifloxacin also exhibits anti-
inflammatory efficacy in vivo. [56]The anti-inflammatory attribute may enhance its efficacy in
the treatment of ocular infections with an inflammatory component and warrants further
investigation. [56] The newer topical fluoroquinolones gemifloxacin and pazufloxacin are
considered as effective as moxifloxacin and levofloxacin for topical prophylaxis and for the
treatment of Staphylococcus aureus-induced endophthalmitis in the rabbit model. [57]
Early diagnosis and appropriate treatment with intravitreous antibiotics are the most impor‐
tant factors for the successful management of endophthalmitis. [58,59] The intraocular
concentration of antibiotics after intravitreous injection is far greater than that achieved by
topical modalities. Drug combinations are necessary to cover the full range of bacteria causing
endophthalmitis. [58,59] Vancomycin (1 mg/0.1 ml) is considered the drug of choice for gram-
positive organisms. Controversy remains concerning the best choice against gram-negative
bacteria. Aminoglycosides (amikacin, 0.4 mg/0.1 ml) have traditionally been recommended
for gram-negative coverage. However, because of their possible role in macular toxicity, recent
trends have shifted to using ceftazidime (2.25 mg/0.1 ml) in combination with vancomycin.
[59] Intracameral or intravitreal cefuroxime at a dose of 1 mg is considered effective in the
treatment of endophthalmitis. [60] Electroretinographic (ERG) and histologic findings
indicated that a dose of 1 mg cefuroxime, administered intravitreally, is not toxic to the rabbit
retina. [60] A dose of 10 mg, injected intravitreally, induce transient physiological effects, and
is toxic to the rabbit retina, as was evident by the permanent reduction in the ERG responses
and by the structural damage to the retina with signs of glial activation. [60] The long-term
outcomes of early intravitreal treatment of endogenous bacterial endophthalmitis, defined as
intravitreal and systemic antibiotics administered within 24 h of diagnosis, with conservative
use of pars plana vitrectomy is considered to provide a relatively favourable visual prognosis.
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[61] The longer the time between onset of ocular symptoms and intravitreal antibiotic injection
is correlated with worse visual outcomes, and it is also associated with increased mortality.
[61] Mortality is also associated with methicillin-resistant Staphylococcus aureus infection. [61]
Methicillin-resistant Sthapylococcus aureus isolates are reported sensitive to vancomycin, and
68% were sensitive to the fourth-generation fluoroquinolones. [62] No significant differences
are reported in visual acuity outcomes of endophthalmitis caused by methicillin-sensitive
Sthaphylococcus aureus versus methicillin-resistant Staphylococcus aureus treated early
intravitreal vancomycin and either ceftazidime or amikacin.[62] Adjunt use of intravitreal
dexamethasone in endogenous endophthalmitis is recommended. [63] No adverse events is
attributed to the dexamethasone, and it appears safe and may be of benefit in endogenous
endophthalmitis. [63] The advantage of corticotherapy combined with specific anti-infective
treatment has been proven for certain bacterial and fungal infections. Corticosteroids, even in
short-term treatments, is recommended to be prescribed in combination with antibiotics in the
course of infections related to their ability to limit the deleterious effects caused by the
activation of the immune system at the time of certain infections.[64] Such as; Bacillus cereus
causes the most virulent and refractory form of endophthalmitis. Eyes treated with intravitreal
vancomycin in conjunction with dexamethasone injection at 7 days and 14 days show signif‐
icantly less inflammation over iris and vitreous than the eyes treated with intravitreal vanco‐
mycin injection alone.[65] Additionally, at 14 days, the histopathological changes of eyes
treated with vancomycin with dexamethasone show less conjunctival inflammation, mild
iridocyclitis, less vitreous cells, and less choroidal vasculitis and retinitis compared to the
vancomycin treatment alone. [65] Intravitreal injection of vancomycin is considered to improve
the therapeutic outcome of Bacillus cereus endophthalmitis. However, the addition of
dexamethasone to antibiotic treatment is reported to provide a therapeutic benefit over
antibiotic alone. [65]
The fluocinolone acetonide intravitreal implants a sustained drug delivery implant has been
used for patients with posterior uveitis who do not respond to or are intolerant to conventional
treatment. [66] It effectively controls the intraocular inflammation. Visual acuity generally
improves, uveitis recurrences, and the need for immunosuppression decreases. However, the
most common side effect is increased intraocular pressure, and cataract development is also
reported. [66,67] The newly approved dexamethasone implant, Ozurdex, is currently consid‐
ered in the treatment of noninfectious intermediate and posterior uveitis given its efficacy,
safety, and ease of use in the outpatient setting. [68]
Triamcinolone acetonide (TA) is an effective steroid drug for various retinal and choroidal
diseases when delivered intravitreally. [69] It may imply an off-label use and it may be
associated with ocular adverse events. Intravitreal TA is not associated with significant
systemic safety risks. [69] Difluprednate 0.05% ophthalmic emulsion is a potent new topical
corticosteroid that exhibits enhanced penetration, better bioavailability, rapid local metabo‐
lism and strong efficacy, with a low incidence of adverse effects. In June 2008, difluprednate
ophthalmic emulsion 0.05% gained FDA approval in the U.S. for the treatment of postoperative
ocular inflammation and pain. Recently, a multicenter, randomized clinical trial showed
difluprednate to be noninferior to prednisolone acetate 1% dosed twice as often, the current
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standard of care for the acute management of endogenous uveitis in the U.S. Furthermore,
difluprednate proved to have a comparable safety profile. [70]
Intravitreous amphotericin B injection associated with, pars plana vitrectomy, systemic am‐
photericin B therapy, and oral anti-fungal therapy are indicated in the treatment of endoge‐
nous fungal endophthalmitis. [71,72] The most common cause of culture-proven endogenous
fungal endophthalmitis is Candida species. [71] Endogenous Aspergillus endophthalmitis
usually has an acute onset of intraocular inflammation and often has a characteristic chorioreti‐
nal lesion located in the macula. (Fig 6] [72] Although treatment with pars plana vitrectomy
and intravitreous amphotericin B is capable of eliminating the ocular infection, the visual out‐
come generally is poor, especially when there is direct macular involvement. [72] The overall
visual outcomes are reported more favorable for Candida cases than they are for Aspergillus
cases. [71] Infection site, illness severity, neutropenia, hemodynamic status, organ failure and
concomitant drug treatments are host-related factors that influence the choice of systemic anti-
fungal treatment. [73] In general, echinocandins are currently favored for empiric treatment of
candidemia, especially in critically ill patients or those with previous azole exposure. Essential‐
ly, patients who have been previously exposed to azoles have a higher probability of being in‐
fected by azole-resistant or non-albicans strains. [73] Pharmacokinetic properties and side
effects suggest that polyenes should be avoided in patients with renal failure, and that echino‐
candins and azoles should be avoided in patients with severe hepatic dysfunction. [73] Intravi‐
treal corticosteroid therapy which is also indicated in conjunction with anti-fungals with and
without vitrectomy, reduces the intraocular inflammatory process and secondary complica‐
tions associated with fungalendophthalmitis. [74]
Figure 6. A. Aspergillus chorioretinal infiltrate in macula of patient with a history of intravenous drug abuse. B. After
treatment with vitrectomy, intravitreal amphotericin B injection, and systemic amphotericin B, the infection resolved
and a macular scar remains. (Weishaar PD, Flynn HW Jr, Murray TG et al: Endogenous Aspergillus endophthalmitis:
Clinical features and treatment outcomes. Ophthalmology 105:57, 1998.)
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Tumor  Necrosis  Factor-Alpha  (TNFα)  is  a  potent  mediator  of  acute  inflammatory  reac‐
tions via activation of proinflammatory signaling cascades. [75] TNFα is a cytokine secret‐
ed  by  macrophages  and  neutrophils,  and  is  important  in  upregulating  cell  adhesion
expression on vascular  endothelial  cells.  [75]  TNFα also stimulates  mononuclear  phago‐
cytes to produce cytokines, such as interlekin (IL)-1, IL-6 and itself. [75] In an experimen‐
tal rat model of Staphylococcus aureus  endophthalmitis, TNFα and IL-1β were detected in
the vitreous within 6 h of intravitreal inoculation. [76] It has been shown that the upregu‐
lation  of  proinflammatory  cytokines  may  have  contributed  to  the  breakdown  of  the
blood-retina barrier, and the recruitment of neutrophils into the eye. [76] Upregulation of
TNFα, IL-1β, and interferon gamma (IFNγ) have also been shown in experimental Staphy‐
lococcus epidermidis endophthalmitis.[77] Injection of TNFα into the vitreous of rabbits and
rats induced increased vascular permeability and cellular infiltration. [78,79] Studies have
also demonstrated upregulation of TNFα and other proinflammatory cytokines in experi‐
mental  autoimmune  uveoretinitis.  [80]  No  studies  have  quantified  cytokines  or  chemo‐
kines in the human eye during endophthalmitis, but based on experimental studies, it is
reasonable to hypothesize that proinflammatory cytokines are key mediators of acute in‐
flammation during endophthalmitis. The primary function of innate immunity is to detect
invading pathogens and clear them as quickly as possible. [80] During an acute intraocu‐
lar infection, a primary and essential component of this response is neutrophil influx. Cel‐
lular  infiltration  in  human  endophthalmitis  cases  has  been  described  as  vitritis,  the
presence of  a hypopyon, and corneal  ring abscess formation.  Experimental  models have
identified polymorphonuclear leukocytes (PMN) as the primary infiltrating cell type dur‐
ing bacterial endophthalmitis.[81-84]The recruitment and activation of neutrophils within
an infected eye is a biological dilemma. PMN infiltration is necessary for bacterial clear‐
ance,  but  the  generation of  toxic  reactive  oxygen intermediates  and other  inflammatory
mediators by PMN may result in bystander damage to delicate tissues of the retina.[81,82]
Robust inflammation is a hallmark of endophthalmitis caused by B. cereus and other types
of  virulent  bacteria.  In  experimental  B.  cereus  endophthalmitis,  inflammatory  cells  were
observed in the posterior chamber in close proximity to the optic nerve head as early as 4
h postinfection.  [82]  Further  analysis  confirms that  the  primary infiltrating cells  are  the
PMNs. The numbers of CD18+/Gr-1+  PMN were minimal at  4 and 6 h postinfection, but
increased significantly thereafter.  The influx of CD18+/Gr-1+  PMN into the posterior seg‐
ment occurred simultaneously with the increase of TNFα in the eye at approximately 4–6
h postinfection.[82] Despite their potential importance, the roles of TNFα and several oth‐
er cytokines in endophthalmitis remain unexplored. Regulation of inflammation is the key
to removing the pathogen without harming the eye, but bystander damage from infiltrat‐
ing cells might occur. For Staphylococcus aureus  endophthalmitis, depletion of neutrophils
early in the inflammatory response reduces the severity of host inflammation, but severe‐
ly hamperes bacterial clearance, resulting in a more severe infection. [81] Pathogen recog‐
nition  and a  well-regulated  inflammatory  response  to  infection  are  essential  in  clearing
invading organisms with minimal damage to surrounding tissue. A tightly controlled re‐
sponse is even more critical in the eye, where non-regenerative cells and tissues responsi‐
ble  for  vision  reside.  Experimental  models  of  bacterial  endophthalmitis  have
Recent Advances in Infective Endocarditis116
demonstrated that once a pathogen is introduced into the posterior segment, an acute re‐
sponse occurs, including synthesis of proinflammatory cytokines and influx of PMN into
the  eye.[83,84]  In  the  case  of  virulent  pathogens  such as  Staphylococcusaureus  or  Bacillus
cereus,  low numbers  of  bacteria  can be cleared effectively by an adequate  inflammatory
response.[83] Once an inoculum threshold is passed, bacterial growth and toxin produc‐
tion overwhelm the inflammatory response.  In an exhaustive attempt to clear  the infec‐
tion,  PMN  fill  the  posterior  and  anterior  segments.  Because  the  absence  of  TNFα  has
beendemonstrated to dampen the initial inflammatory response during Bacillus cereus  en‐
dophthalmitis, several studies have also analyzed whether therapy targeting TNFα would
effectively attenuate inflammation. The anti-inflammatory potential of anti-TNFα has been
shown  after  injected  immediately  prior  to  Bacillus  cereus  infection.[82]  Infliximab,  anti-
TNFα antibody has attenuated intraocular inflammation in experimental  models of  cho‐
roidal  neovascularization,  endotoxin-induced  uveitis,  and  in  human  uveitis  patients.
[85-88]  Infliximab  was  recently  shown to  be  non-toxic  at  levels  up  to  1.7  mg in  rabbit
eyes. [89]
These findings suggest the potential for attenuation of inflammation during endophthalmitis
by targeting TNFα and perhaps other cytokines, but this sort of therapy would likely be best
suited for the initial stages of infection.[90] Continuing studies will determine the therapeutic
potential of cytokine targeting in conjunction with early antibiotic treatment in reducing
inflammation during endogenous endophthalmitis.
4. Future directions
Since AR has been advocated as an important therapeutic target to treat oxidative stress-
induced inflammatory disorders including ocular inflammation, detailed studies of the
molecular events and clear understanding of AR’s involvement in the pathogenesis of
inflammation is required. Understanding this role of AR should provide pharmacological tools
for eventual therapeutic interventions to control cell proliferation, apoptosis, tissue repair, and
prevention of the cytotoxicity of cytokines and chemokines which are elevated during ocular
inflammation. More importantly, these studies will provide a mechanistic link between AR
with ocular inflammation. Studies using various animal models are required to clearly
understand the mechanism of AR’s involvement in the inflammation and related pathologies
which in turn will help in the design and synthesis of more specific inhibitors. Common
limitations for some of the earlier AR inhibitors (ARI) such as sorbinil and tolrestat include
critical hepatic and renal toxicity for long-term use. [91] Newer AR inhibitors such as zopol‐
restat, raneristat and fidarestat are now being tested for their ability to prevent the progression
of diabetic neuropathy. Since these drugs have already passed in the Food and Drug Admin‐
istration (FDA)’s phase I and II clinical trials and have been found to be safe without any major
irreversible side effects, and it is expected that ARI such as fidarestat could be developed as
novel therapy for preventing ocular inflammation especially uveitis in a relatively shorter time.
[92-94]
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